S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

$2.57
-0.23 (-8.21%)
(As of 03/28/2024 ET)
Today's Range
$2.52
$2.94
50-Day Range
$2.02
$2.86
52-Week Range
$1.14
$3.33
Volume
2.26 million shs
Average Volume
1.82 million shs
Market Capitalization
$252.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Gritstone bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
133.5% Upside
$6.00 Price Target
Short Interest
Bearish
9.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Gritstone bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.94) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

831st out of 939 stocks

Biological Products, Except Diagnostic Industry

142nd out of 156 stocks

GRTS stock logo

About Gritstone bio Stock (NASDAQ:GRTS)

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

GRTS Stock Price History

GRTS Stock News Headlines

Gritstone bio Sees Unusually Large Options Volume (NASDAQ:GRTS)
GRTS Gritstone bio, Inc.
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
GRTS Apr 2024 0.500 put
GRTS Aug 2024 0.500 put
Why Is Gritstone Bio Stock Trading Lower?
Gritstone Bio To Cut 40% Of Workforce
Gritstone bio Announces Workforce Reduction
GRTS Mar 2024 1.000 put
GRTS Apr 2024 5.000 call
GRTS Mar 2024 2.500 put
GRTS Mar 2024 1.500 put
GRTS Apr 2024 2.000 call
GRTS Feb 2024 2.000 call
See More Headlines
Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
231
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+133.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-138,490,000.00
Net Margins
-847.24%
Pretax Margin
-847.34%

Debt

Sales & Book Value

Annual Sales
$16.34 million
Book Value
$0.54 per share

Miscellaneous

Free Float
93,545,000
Market Cap
$252.04 million
Optionable
Optionable
Beta
0.39
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Andrew R. Allen BCh (Age 58)
    BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director
    Comp: $983.44k
  • Mr. Erin E. Jones M.S. (Age 52)
    Executive VP & COO
    Comp: $658.01k
  • Dr. Karin Jooss Ph.D. (Age 58)
    Executive VP and Head of Research & Development
    Comp: $706.07k
  • Ms. Vassiliki Economides (Age 43)
    Executive VP & CFO
  • Mr. James Cho
    Chief Accounting Officer
  • George MacDougall
    Director of Investor Relations & Corporate Communications
  • Ms. Stacy Proctor
    Executive VP & Chief People Officer
  • Dr. Matthew J. Hawryluk M.B.A. (Age 46)
    Ph.D., Executive VP & Chief Business Officer

GRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings
or view top-rated stocks.

What is Gritstone bio's stock price target for 2024?

3 brokers have issued 12-month price targets for Gritstone bio's stock. Their GRTS share price targets range from $4.00 to $7.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price.
View analysts price targets for GRTS
or view top-rated stocks among Wall Street analysts.

How have GRTS shares performed in 2024?

Gritstone bio's stock was trading at $2.04 at the beginning of 2024. Since then, GRTS shares have increased by 26.0% and is now trading at $2.57.
View the best growth stocks for 2024 here
.

Are investors shorting Gritstone bio?

Gritstone bio saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 8,820,000 shares, an increase of 7.3% from the February 29th total of 8,220,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 4.3 days. Approximately 9.9% of the company's shares are short sold.
View Gritstone bio's Short Interest
.

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GRTS earnings forecast
.

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $10.38 million for the quarter, compared to analysts' expectations of $4.80 million. Gritstone bio had a negative trailing twelve-month return on equity of 147.22% and a negative net margin of 847.24%.

What ETF holds Gritstone bio's stock?

Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

Gritstone bio (GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.63%), Vanguard Group Inc. (4.50%), Point72 Asset Management L.P. (4.17%), Frazier Life Sciences Management L.P. (1.08%), Northern Trust Corp (0.77%) and Charles Schwab Investment Management Inc. (0.28%). Insiders that own company stock include Erin Jones and Vassiliki Economides.
View institutional ownership trends
.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners